Allergan plc (NYSE:AGN) Shares Acquired by World Asset Management Inc
World Asset Management Inc increased its position in Allergan plc (NYSE:AGN) by 1.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 16,983 shares of the company’s stock after buying an additional 205 shares during the quarter. World Asset Management Inc’s holdings in Allergan were worth $2,843,000 at the end of the most recent reporting period.
Several other institutional investors have also recently made changes to their positions in AGN. Dimensional Fund Advisors LP increased its position in Allergan by 0.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,606,982 shares of the company’s stock worth $214,787,000 after purchasing an additional 13,100 shares in the last quarter. Geode Capital Management LLC grew its holdings in Allergan by 6.6% in the 4th quarter. Geode Capital Management LLC now owns 4,000,839 shares of the company’s stock valued at $533,767,000 after buying an additional 247,743 shares during the period. Two Sigma Advisers LP purchased a new stake in Allergan in the 4th quarter valued at about $708,000. Macquarie Group Ltd. grew its holdings in Allergan by 2.6% in the 4th quarter. Macquarie Group Ltd. now owns 94,358 shares of the company’s stock valued at $12,612,000 after buying an additional 2,382 shares during the period. Finally, FMR LLC grew its holdings in Allergan by 6.1% in the 4th quarter. FMR LLC now owns 4,253,740 shares of the company’s stock valued at $568,554,000 after buying an additional 245,322 shares during the period. Institutional investors and hedge funds own 80.06% of the company’s stock.
Several research firms have commented on AGN. Sanford C. Bernstein cut Allergan from an “outperform” rating to a “market perform” rating and set a $166.08 price target for the company. in a report on Tuesday, July 16th. TheStreet upgraded Triton International from a “d-” rating to a “c” rating in a report on Friday, July 12th. Barclays lowered their price target on from GBX 320 ($4.18) to GBX 290 ($3.79) and set an “overweight” rating for the company in a report on Tuesday, June 25th. Jefferies Financial Group began coverage on Pinduoduo in a report on Monday, April 15th. They issued a “buy” rating and a $30.00 price target for the company. Finally, Leerink Swann cut Allergan from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $217.00 to $188.00 in a report on Thursday, July 18th. Two equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and eight have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $175.48.
Allergan (NYSE:AGN) last announced its earnings results on Tuesday, May 7th. The company reported $3.79 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.55 by $0.24. Allergan had a positive return on equity of 8.45% and a negative net margin of 45.94%. The company had revenue of $3.60 billion for the quarter, compared to analyst estimates of $3.55 billion. During the same period in the prior year, the company posted $3.74 EPS. Allergan’s quarterly revenue was down 2.0% on a year-over-year basis. On average, analysts expect that Allergan plc will post 16.74 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, September 13th. Stockholders of record on Tuesday, August 13th will be issued a dividend of $0.74 per share. This represents a $2.96 annualized dividend and a dividend yield of 1.84%. The ex-dividend date is Monday, August 12th. Allergan’s dividend payout ratio is 17.74%.
Allergan Company Profile
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.
Featured Article: Does a trade war provide a risk to the global economy?
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.